Brief: PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
12/02/2024 12:36
Feb 12 (Reuters) - PolyPid Ltd PYPD.O :
* POLYPID ANNOUNCES ENROLLMENT OF THE 100TH PATIENT IN THE
ONGOING
SHIELD II PHASE 3 TRIAL
* POLYPID LTD - TOP-LINE RESULTS EXPECTED IN SECOND HALF OF
2024
* POLYPID LTD: ABOUT 40 CENTERS CURRENTLY OPEN
* POLYPID: TO CONDUCT UNBLINDED INTERIM ANALYSIS ONCE TOTAL
OF
ABOUT 400 PATIENTS COMPLETE 30-DAY FOLLOW-UP, EXPECTED TO OCCUR
IN MID-2024
* POLYPID: RECENT $16 MILLION FINANCING EXTENDS CO'S CASH
RUNWAY
THROUGH LATE Q3 2024 & BEYOND EXPECTED TIMING OF UNBLINDED
INTERIM ANALYSIS
Source text for Eikon: ID:nGNX36lDG5
Further company coverage: PYPD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA